Le projet MP5: Gestion de la maintenance assistée par ordinateur

L'année 2000 marque un tournant dans la manière d'appréhender l'activité de maintenance dans la division ST. Les méthodes, jusqu'alors basées sur une approche corporative relayée par des outils informatiques d'ancienne génération, ont évolué vers une approche intégrée. Ce document décrit tous les aspects du projet de migration de l'ancien logiciel RAPIER vers le nouveau logiciel MP5: définition des ressources, identification des contraintes et des facteurs de succès critiques, planification, unification des méthodes et des données, migration informatique, formation du personnel et mise en service. Il présente également les intégrations réalisées avec d'autres logiciels, les possibilités d'évolution pour la division et les perspectives de généralisation pour le CERN

TCR industrial system integration strategy

New turnkey data acquisition systems purchased from industry are being integrated into CERN's Technical Data Server. The short time available for system integration and the large amount of data per system require a standard and modular design. Four different integration layers have been defined in order to easily 'plug in' industrial systems. The first layer allows the integration of the equipment at the digital I/O port or fieldbus (Profibus-DP) level. A second layer permits the integration of PLCs (Siemens S5, S7 and Telemecanique); a third layer integrates equipment drivers. The fourth layer integrates turnkey mimic diagrams in the TCR operator console. The second and third layers use two new event-driven protocols based on TCP/IP. Using this structure, new systems are integrated in the data transmission chain, the layer at which they are integrated depending only on their integration capabilities

CERN LHC Technical Infrastructure Monitoring (TIM)

The CERN Large Hadron Collider (LHC) will start to deliver particles to its experiments in the year 2005. However, all the primary services such as electricity, cooling, ventilation, safety systems and others such as vacuum and cryogenics will be commissioned gradually between 2001 and 2005. This technical infrastructure will be controlled using industrial control systems, which have either already been purchased from specialized companies or are currently being put together for tender. This paper discusses the overall architecture and interfaces that will be used by the CERN Technical Control Room (TCR) to monitor the technical services at CERN and those of the LHC and its experiments. The issue of coherently integrating existing and future control systems over a period of five years with constantly evolving technology is addressed. The paper also summarizes the functionality of all the tools needed by the control room such as alarm reporting, data logging systems, man machine interfaces and the console manager. Particular attention is paid to networking aspects, so that reliable and timely transmission of data can be assured. A pyramidal layered component architecture is compared with a complete SCADA solution

Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer.

The early detection of breast cancer is the best means to minimise disease-related mortality. Current screening techniques have limited sensitivity and specificity. Breast nipple aspirate fluid can be obtained noninvasively and contains proteins secreted from ductal and lobular epithelia. Nipple aspirate fluid proteins are breast specific and generally more concentrated than corresponding blood levels. Proteomic analysis of 1 microl of diluted nipple aspirate fluid over a 5-40 kDa range from 20 subjects with breast cancer and 13 with nondiseased breasts identified five differentially expressed proteins. The most sensitive and specific proteins were 6500 and 15 940 Da, found in 75-84% of samples from women with cancer but in only 0-9% of samples from normal women. These findings suggest that (1) differential expression of nipple aspirate fluid proteins exists between women with normal and diseased breasts, and (2) analysis of these proteins may predict the presence of breast cancer

Transcription profiles of non-immortalized breast cancer cell lines

BACKGROUND: Searches for differentially expressed genes in tumours have made extensive use of array technology. Most samples have been obtained from tumour biopsies or from established tumour-derived cell lines. Here we compare cultures of non-immortalized breast cancer cells, normal non-immortalized breast cells and immortalized normal and breast cancer cells to identify which elements of a defined set of well-known cancer-related genes are differentially expressed. METHODS: Cultures of cells from pleural effusions or ascitic fluids from breast cancer patients (MSSMs) were used in addition to commercially-available normal breast epithelial cells (HMECs), established breast cancer cell lines (T-est) and established normal breast cells (N-est). The Atlas Human Cancer 1.2 cDNA expression array was employed. The data obtained were analysed using widely-available statistical and clustering software and further validated through real-time PCR. RESULTS: According to Significance Analysis of Microarray (SAM) and AtlasImage software, 48 genes differed at least 2-fold in adjusted intensities between HMECs and MSSMs (p < 0.01). Some of these genes have already been directly linked with breast cancer, metastasis and malignant progression, whilst others encode receptors linked to signal transduction pathways or are otherwise related to cell proliferation. Fifty genes showed at least a 2.5-fold difference between MSSMs and T-est cells according to AtlasImage, 2-fold according to SAM. Most of these classified as genes related to metabolism and cell communication. CONCLUSION: The expression profiles of 1176 genes were determined in finite life-span cultures of metastatic breast cancer cells and of normal breast cells. Significant differences were detected between the finite life-span breast cancer cell cultures and the established breast cancer cell lines. These data suggest caution in extrapolating information from established lines for application to clinical cancer research

Proteomic analysis reveals that 14-3-3 sigma in downregulated in human breast cancer cells

The class of molecular chaperones known as 14-3-3 is involved in the control of cellular growth by virtue of its apparent regulation of various signaling pathways, including the Raf/mitogen-activated protein kinase pathway. In breast cancer cells, the sigma form of 14-3-3 has been shown to interact with cyclin-dependent kinases and to control the rate of entry into mitosis. To test for a direct role for 14-3-3 in breast epithelial cell neoplasia, me have quantitated 14-3-3 protein levels using a proteomic approach based on two-dimensional electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF). We show here that 14-3-3 sigma protein is strongly down-regulated in the prototypic breast cancer cell lines MCF-7 and MDA-MB-231 and in primary breast carcinomas as compared with normal breast epithelial cells. In contrast, levels of the alpha, beta, delta, or zeta isoforms of 14-3-3 mere the same in both normal and transformed cells. The data support the idea that 14-3-3 sigma is involved in the neoplastic transition of breast epithelial cells by virtue of its role as a tumor suppressor; as such, it may constitute a robust marker with clinical efficacy for this pathology

Design of glycosyltransferase inhibitors targeting human O-GlcNAc transferase (OGT)

International audienceInhibition of glycosyltransferases requires the design of neutral inhibitors to allow cell permeation in contrast to their natural dianionic substrates. O-GlcNAc transferase (OGT) is a key enzyme involved in dynamic glycosylation of cytosolic and nuclear proteins in competition with phosphorylation. Designing OGT inhibitors is of prime interest for the better understanding of its biological implications. Introduction of a pyridine moiety as a pyrophosphate surrogate was evaluated, which provided moderate in vitro inhibition of OGT. Docking studies highlighted some key features for the binding of the designed inhibitors to the catalytic site of OGT where the carbohydrate moiety did not occupy its natural position but rather turned away and pointed to the solvent outside the catalytic pocket. Further investigation with cellular assays did not provide inhibition of OGT. This lack of OGT inhibition was rationalized with a permeation assay which revealed the sequestration of the inhibitors at the membrane